Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). MicroPort NeuroTech's share price for the quarter that ended in Dec. 2023 was HK$12.24. MicroPort NeuroTech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 582.7 Mil. Therefore, MicroPort NeuroTech's market cap for the quarter that ended in Dec. 2023 was HK$7,131.7 Mil.
MicroPort NeuroTech's quarterly market cap
declined
from Dec. 2022 (HK$13,372.0 Mil) to Jun. 2023 (HK$8,098.9 Mil) and
declined
from Jun. 2023 (HK$8,098.9 Mil) to Dec. 2023 (HK$7,131.7 Mil).
MicroPort NeuroTech's annual market cap
increased
from Dec. 2021 (HK$0.0 Mil) to Dec. 2022 (HK$13,372.0 Mil) but then
declined
from Dec. 2022 (HK$13,372.0 Mil) to Dec. 2023 (HK$7,131.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. MicroPort NeuroTech's Enterprise Value for Today is HK$4,149.2 Mil.
MicroPort NeuroTech Market Cap Historical Data
The historical data trend for MicroPort NeuroTech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MicroPort NeuroTech's Market Cap
For the Medical Devices subindustry, MicroPort NeuroTech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroPort NeuroTech's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroPort NeuroTech's Market Cap distribution charts can be found below:
* The bar in red indicates where MicroPort NeuroTech's Market Cap falls into.
MicroPort NeuroTech Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
MicroPort NeuroTech's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroPort NeuroTech (HKSE:02172) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
MicroPort NeuroTech Market Cap Related Terms
Thank you for viewing the detailed overview of MicroPort NeuroTech's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
MicroPort NeuroTech (HKSE:02172) Business Description
MicroPort NeuroTech Ltd is into the neuro-interventional medical device industry, dedicated to providing innovative solutions for physicians and patients. The company boast a comprehensive portfolio of approved therapeutic products covering all of the three main areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02172 has been successfully added to your